Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Jul 6;12:633540. doi: 10.3389/fimmu.2021.633540

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2021 Insuela, Ferrero, Gonçalves-de-Albuquerque, Chaves, da Silva, Castro-Faria-Neto, Simões, Barja-Fidalgo, Silva, Martins, Silva and Carvalho

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

GcgR antagonist did not alter glycemia and systemic inflammation in diabetic mice after CLP induction. CLP was performed 21 days after diabetes induction, and the treatment with GcgR antagonist was carried out 24h and 1h before CLP. (A) Glycemia. (B) Analysis of blood neutrophil numbers. (C) Plasma levels of CXCL1/KC. For (A, B) analysis were realized 3h after CLP. For (C) analysis was realized 20h after CLP. Each value represents the mean ± S.E.M. For (B), each sample value was obtained in blinded and randomized counting. The statistical analysis was performed by one-way ANOVA, followed by Newman–Keuls–Student’s t-test. Results are representative of one individual assay. ⁺ P < 0.05 compared to sham non-diabetic mice. ^& P < 0.05 compared to CLP non-diabetic mice. CLP, Cecum ligation and puncture; GcgR Ant, GcgR Antagonist.